Incyte (INCY) EVP Patrick Mayes receives 4,218 stock options at $106.21

Rhea-AI Filing Summary

Incyte Corporation executive Patrick A. Mayes, EVP & Chief Scientific Officer, reported a grant of 4,218 employee stock options on January 16, 2026. These options have an exercise price of $106.21 per share and give the right to buy Incyte common stock.

Beginning January 16, 2026, the options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remaining portion vesting monthly over the following three years, and they expire on January 15, 2036. After this award, Mayes beneficially owns 4,218 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mayes Patrick A

Role EVP & Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	4,218	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 4,218 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mayes Patrick A

(Last) (First) (Middle)

1801 AUGUSTINE CUT-OFF

(Street)

WILMINGTON DE 19803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$106.21	01/16/2026		A		4,218		(1)	01/15/2036	Common Stock	4,218	$0	4,218	D

Explanation of Responses:

1. Beginning January 16, 2026, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remainder vesting monthly over three years.

Remarks:

	/s/ Elizabeth Feeney, Attorney-In-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did INCYTE CORP (INCY) report for Patrick A. Mayes?

The filing shows that EVP & Chief Scientific Officer Patrick A. Mayes was granted 4,218 employee stock options on January 16, 2026.

What is the exercise price of Patrick A. Mayes’s new Incyte (INCY) stock options?

The employee stock options granted to Patrick A. Mayes have an exercise price of $106.21 per share for Incyte common stock.

How do the newly granted INCY stock options vest for Patrick A. Mayes?

Starting January 16, 2026, the options vest in 37 installments, with the first 25% vesting on July 15, 2026 and the remainder vesting monthly over three years.

When do Patrick A. Mayes’s Incyte (INCY) stock options expire?

The employee stock options reported for Patrick A. Mayes have an expiration date of January 15, 2036.

How many Incyte derivative securities does Patrick A. Mayes own after this Form 4 transaction?

Following the reported grant, Patrick A. Mayes beneficially owns 4,218 derivative securities (employee stock options) directly.

What role does Patrick A. Mayes hold at Incyte (INCY)?

Patrick A. Mayes is reported as an Officer of Incyte, serving as EVP & Chief Scientific Officer.